Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis

The burden of tuberculosis is compounded by drug-resistant forms of the disease. This study aimed to analyse data on antituberculosis drug resistance gathered by the WHO and International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Da...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2006-12, Vol.368 (9553), p.2142-2154
Main Authors: Aziz, Mohamed Abdel, Wright, Abigail, Laszlo, Adalbert, De Muynck, Aimé, Portaels, Françoise, Van Deun, Armand, Wells, Charles, Nunn, Paul, Blanc, Leopold, Raviglione, Mario
Format: Article
Language:English
Subjects:
Antitubercular Agents - therapeutic use
Biological and medical sciences
Data analysis
Data collection
Data Collection - methods
Developing countries
Epidemiology
General aspects
Global Health
HIV
Human immunodeficiency virus
Humans
Isoniazid - therapeutic use
LDCs
Medical sciences
Methods
Miscellaneous
Mycobacterium tuberculosis - isolation & purification
Patients
Population Surveillance - methods
Prevalence
Public health. Hygiene
Public health. Hygiene-occupational medicine
Rifampin - therapeutic use
Surveillance
Testing
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The burden of tuberculosis is compounded by drug-resistant forms of the disease. This study aimed to analyse data on antituberculosis drug resistance gathered by the WHO and International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Data on drug susceptibility testing for four antituberculosis drugs—isoniazid, rifampicin, ethambutol, and streptomycin—were gathered in the third round of the Global Project (1999–2002) from surveys or ongoing surveillance in 79 countries or geographical settings. These data were combined with those from the first two rounds of the project and analyses were done. Countries that participated followed a standardised set of guidelines to ensure comparability both between and within countries. The median prevalence of resistance to any of the four antituberculosis drugs in new cases of tuberculosis identified in 76 countries or geographical settings was 10·2% (range 0·0–57·1). The median prevalence of multidrug resistance in new cases was 1·0% (range 0·0–14·2). Kazakhstan, Tomsk Oblast (Russia), Karakalpakstan (Uzbekistan), Estonia, Israel, the Chinese provinces Liaoning and Henan, Lithuania, and Latvia reported prevalence of multidrug resistance above 6·5%. Trend analysis showed a significant increase in the prevalence of multidrug resistance in new cases in Tomsk Oblast (p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(06)69863-2